Difference between revisions of "Part:BBa K1011000:Design"
 
Line 6: Line 6:
  
 
===Design Notes===
 
===Design Notes===
−
There is an illegal EcoR1 restriction site at bp 102-107 of the gene.  We changed the C at site 107 to a T, which maintained the codon optimization and removed the illegal restriction site.
+
There was an illegal EcoR1 restriction site at bp 102-107 of the gene.  We changed the C at site 107 to a T, which maintained the codon optimization and removed the illegal restriction site.
  
  

Latest revision as of 01:47, 28 September 2013

ftsZ gene from E. coli on pSB1C3


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal AgeI site found at 322
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

There was an illegal EcoR1 restriction site at bp 102-107 of the gene. We changed the C at site 107 to a T, which maintained the codon optimization and removed the illegal restriction site.


Source

The organism for which we based our sequence is Escherichia coli str. K-12 substr. MG1655, located at the following NCBI url:

http://www.ncbi.nlm.nih.gov/nuccore/NC_000913.2?report=genbank&from=105305&to=106456

References

The European CanCer Organisation (ECCO). (2012, November 7). First trial in humans of 'minicells': A completely new way of delivering anti-cancer drugs. Science Daily, Retrieved from http://www.sciencedaily.com/releases/2012/11/121108181443.htm

Flemming, A. (2007). Minicells deliver lethal load to tumours. Nature Reviews Drug Discovery, 6, 519. doi: 10.1038/nrd2366.

Giacalone, M. J. et al. (2007). Immunization with non-replicating e. coli minicells delivering both protein antigen and dna protects mice from lethal challenge with lymphocytic choriomeningitis virus. Vaccine,25(12), 2279-2287. doi: 10.1016/j.vaccine.2006.11.069.

MacDiarmid, J. A., & Brahmbhatt, H. (2011). Minicells: Versatile vectors for targeted drug or si/shrna cancer therapy. Current Opinion in Biotechnology, 22, 909-916. doi: 10.1016/j.copbio.2011.04.008

MacDiarmid, J. A. et al. (2009). Sequential treatment of drug-resistant tumors with targetedminicells containing sirna or a cytotoxic drug. Nature Biotechnology,27(7), 643-654. doi: 10.1038/nbt.1547.

MacDiarmid, J. A. et al. (2007). Bacterial derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell, 11, 431-445. doi: 10.1016/j.ccr.2007.03.012.

Ward, J. E., & Lutkenhaus, J. (1985). Overproduction of ftsz induces minicell formation in e. coli. Cell, 42, 941-949. doi: 10.1016/0092-8674(85)90290-9.